Scopolamine Patch Application Site
Apply the scopolamine transdermal patch to the hairless area behind one ear (postauricular area). This is the FDA-approved and guideline-recommended site for all indications 1.
Application Instructions
The patch should be placed on clean, dry, hairless skin in the postauricular region (the area behind the ear over the mastoid process). This specific anatomical location is critical for several reasons:
- Optimal absorption: The postauricular skin provides consistent drug delivery with predictable pharmacokinetics 2
- Minimal hair interference: This naturally hairless area ensures proper patch adhesion
- Convenient access: Easy for patients to apply and remove themselves
Key Application Steps
- Select the site: Choose the hairless area directly behind one ear
- Prepare the skin: Ensure the area is clean and completely dry before application
- Apply the patch: Press firmly to ensure full contact with skin
- Wash hands immediately: Use soap and water thoroughly after applying the patch to prevent accidental eye contamination 1
Important Considerations
If the patch becomes displaced, remove it entirely and apply a new patch behind the other ear 1. Never reapply a displaced patch or apply multiple patches simultaneously.
For prolonged use (beyond 3 days): Remove the first patch and apply a new one behind the opposite ear to allow the first application site to recover 2, 3.
Alternative Sites Are Not Recommended
While research has explored application over salivary glands for drooling management 4, 5, 6, the FDA-labeled indication specifies postauricular application only 1. The postauricular site has been validated through extensive clinical trials for motion sickness and postoperative nausea/vomiting prevention.
Common pitfall: Avoid touching the patch after application, as pressure can cause scopolamine to leak from the edges. Also avoid touching your eyes after handling the patch, as this can cause pupillary dilation and visual disturbances 1.
The patch achieves protective plasma concentrations (approximately 50 pg/mL) within 6-8 hours of postauricular application, with steady-state levels around 100 pg/mL achieved at 8-12 hours 2.